retatrutide clinical trial results 2024 2025 press release Lilly's triple G agonist boasts 28.7% weight loss in Phase III Eli Lilly infiltrates anti-obesity market

People describe feeling sluggish even after a full nights sleep, struggling to concentrate during the day, and lacking the motivation to keep up with normal routines

To reduce the risk of gastrointestinal side effects, a gradual escalation of doses is recommended

Thit k dng vin nang d s dng, c a chung ti M v nhiu quc gia khc trn th gii

ipamorelin's advantage is primarily over the older GHRP class, not over sermorelin specifically

J., Devries, M

People with severe gastrointestinal (GI) disorders, such as gastroparesis or inflammatory bowel disease, should also avoid GLP-1 agonists due to the possibility of exacerbating GI symptoms (23)